Previous 10 | Next 10 |
ESSA Pharma Presents Therapeutic Potential of EPI-7386 at 2020 Virtual American Urological Association (AUA) Annual Meeting Canada NewsWire HOUSTON and VANCOUVER, May 15, 2020 HOUSTON and VANCOUVER , May 15, 2020 /CNW/ - ESSA Pharma Inc. (Nasdaq: EPIX; TSX-V: EPI), a...
ESSA Pharma (NASDAQ: EPIX ): Q2 GAAP EPS of -$0.45 misses by $0.28 . More news on: ESSA Pharma Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
VANCOUVER and HOUSTON, May 7, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financia...
The FDA has notified ESSA Pharma (NASDAQ: EPIX ) that it may proceed with its proposed clinical investigation of EPI-7386 for the treatment of metastatic castration-resistant prostate cancer ("mCRPC"). More news on: ESSA Pharma Inc., Healthcare stocks news, Read more ...
VANCOUVER and HOUSTON , April 30, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the U.S. Food and Drug Administrat...
VANCOUVER and HOUSTON , April 13, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has entered into an Open Market S...
ESSA Pharma (NASDAQ: EPIX ) has submitted an Investigational New Drug (IND) application to the FDA to evaluate EPI-7386 in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). More news on: ESSA Pharma Inc., Healthcare stock...
VANCOUVER and HOUSTON , March 31, 2020 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New...
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences indus...
HOUSTON and VANCOUVER , Feb. 27, 2020 /PRNewswire/ - ESSA Pharma Inc. (" ESSA " or the " Company ") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters...
News, Short Squeeze, Breakout and More Instantly...
ESSA Pharma to Present at the JonesHealthcare Seaside Summit Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , July 8, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on de...
ESSA Pharma to Present at the Jefferies Global Healthcare Conference Canada NewsWire SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , May 30, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focus...